Cerevel Therapeutics Holdings Inc (CERE)
$44.62
+0.22
(+0.5%)▲
Performance
- $44.38$44.66$44.62
0.54%
Downside
Day's Volatility :0.63%
Upside
0.09%
- $19.59$44.62$44.62
56.1%
Downside
52 Weeks Volatility :56.1%
Upside
0.0%
Returns
| Period | Cerevel Therapeutics Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 4.54% | 6.5% | 0.0% |
6 Months | 5.54% | 7.1% | 0.0% |
1 Year | 48.3% | 9.8% | 0.0% |
3 Years | 79.98% | 14.2% | -20.2% |
Highlights
Market Capitalization | 8.1B |
Book Value | $3.1 |
Earnings Per Share (EPS) | -2.73 |
Wall Street Target Price | 43.4 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -29.79% |
Return On Equity TTM | -92.45% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -484.5M |
Diluted Eps TTM | -2.73 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.51 |
EPS Estimate Next Year | -2.8 |
EPS Estimate Current Quarter | -0.61 |
EPS Estimate Next Quarter | -0.62 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 2.73%
Technicals Summary
Sell
Neutral
Buy
Cerevel Therapeutics Holdings Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cerevel Therapeutics Holdings Inc | 13.96% | 5.54% | 48.3% | 79.98% | 349.39% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cerevel Therapeutics Holdings Inc | NA | NA | NA | -2.51 | -0.92 | -0.3 | NA | 3.1 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cerevel Therapeutics Holdings Inc | Hold | $8.1B | 349.39% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Cerevel Therapeutics Holdings Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 13.3%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 106.5%
Institutional Holdings
Bain Capital Investors LLC
36.05%Perceptive Advisors LLC
5.92%venBio Select Advisor LLC
4.15%Vanguard Group Inc
4.10%BlackRock Inc
2.99%State Street Corporation
1.94%
Corporate Announcements
Cerevel Therapeutics Holdings Inc Earnings
Cerevel Therapeutics Holdings Inc’s price-to-earnings ratio stands at None
Read More
Company Information
cerevel therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (cns). the company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of cns disorders, including parkinson’s, alzheimer’s, epilepsy, schizophrenia and addiction. headquartered in the greater boston area, cerevel was formed in 2018 through a partnership between bain capital and pfizer.
Organization | Cerevel Therapeutics Holdings Inc |
Employees | 355 |
CEO | Dr. N. Anthony Coles Jr., M.P.H. |
Industry | Finance |
